{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:44:23Z","timestamp":1776818663026,"version":"3.51.2"},"reference-count":35,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Advanced","award":["NIHR300098"],"award-info":[{"award-number":["NIHR300098"]}]},{"name":"Barts Charity Seed Grant","award":["MEAG2C4R"],"award-info":[{"award-number":["MEAG2C4R"]}]},{"DOI":"10.13039\/100014226","name":"William Harvey Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019154","name":"Clinical Research and Barts Charity","doi-asserted-by":"publisher","award":["MRC0220"],"award-info":[{"award-number":["MRC0220"]}],"id":[{"id":"10.13039\/501100019154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","award":["GN 2272"],"award-info":[{"award-number":["GN 2272"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028027","name":"BTLC","doi-asserted-by":"publisher","award":["MGU0551"],"award-info":[{"award-number":["MGU0551"]}],"id":[{"id":"10.13039\/100028027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/T018496\/1"],"award-info":[{"award-number":["BB\/T018496\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Monoallelic dominant-negative LZTR1 gene variants have been implicated as a cause of Noonan syndrome resulting from hyperactivation of canonical RAS-MAPK signalling. Missense LZTR1 variants have been associated with defective ubiquitination theoretically leading to increased Ras substrate availability and altered p53 signalling. We investigated the role of LZTR1 in this pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single nucleotide substitutions were generated by mutagenesis of an N-terminal MYC tagged-LZTR1-cDNA. Wild-type and variant constructs were expressed in mammalian cells and lysates prepared for phosphoproteomics. Analysis of transcriptomic data was conducted using Ingenuity-Pathway-Analysis. Significant phospho-peptides, protein-protein interactions, and pathways of interest were probed using immunoblotting, immunofluorescence, nanoluciferase assays and in silico modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two heterozygous LZTR1 variants, affiliated with short stature, were shown in vitro to be thermodynamically stable and associated with elevated pan-Ras levels. Phosphoproteomics revealed upregulation of the histone acetyltransferase inhibitor, NOC2L, in both variants. This finding, consistent on immunoblotting and immunofluorescence, was associated with impaired p53 acetylation. Major effectors of the DNA damage response were preferentially activated in LZTR1 variants. Despite an apparent activation of the DNA damage response and diminished p53 activity, levels of LC3 and phosphorylated-p70 S6 kinase were increased. In silico structure modelling and nanoluciferase assays suggested that LZTR1 interacts with NOC2L, an interaction disrupted in both LZTR1 variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NOC2L and p53 form a complex that dictates p53 activation. We demonstrate a previously unknown interaction between NOC2L and LZTR1 and hypothesize that LZTR1 acts as a binding factor modulating activity of this complex. Because NOC2L negatively regulates p53, its upregulation leads to p53-mediated transcription inhibition. LZTR1 attenuation resulting from genetic mutations associated with Noonan syndrome, potentiate NOC2L activity leading to reduced apoptosis and a compensatory increase in autophagy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf602","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:07:10Z","timestamp":1761916030000},"page":"1418-1430","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenesis of Noonan Syndrome is Modulated by NOC2L, a Novel Interactor of LZTR1 Leading to Impaired P53 Signalling"],"prefix":"10.1210","volume":"111","author":[{"given":"Sumana","family":"Chatterjee","sequence":"first","affiliation":[{"name":"Centre for Endocrinology, William Harvey Research Institute, QMUL , London, EC1M 6BQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-2273","authenticated-orcid":false,"given":"Miho","family":"Ishida","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, William Harvey Research Institute, QMUL , London, EC1M 6BQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9bora R","family":"Bertola","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of S\u00e3o Paulo , S\u00e3o Paulo 05403-000 ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Chizo","family":"Agwu","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences, College of Medicine and Dental Sciences, University of Birmingham , Birmingham, B15 2TT ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6793-3118","authenticated-orcid":false,"given":"Carles","family":"Gaston-Massuet","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, William Harvey Research Institute, QMUL , London, EC1M 6BQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam J","family":"McGuffin","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading , Reading, RG6 6AS ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-1931","authenticated-orcid":false,"given":"Helen L","family":"Storr","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, William Harvey Research Institute, QMUL , London, EC1M 6BQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8051-3866","authenticated-orcid":false,"given":"Avinaash V","family":"Maharaj","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, William Harvey Research Institute, QMUL , London, EC1M 6BQ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"9863","key":"2026042119564885200_dgaf602-B1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"2026042119564885200_dgaf602-B2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.beem.2010.09.002","article-title":"Noonan syndrome and clinically related disorders","volume":"25","author":"Tartaglia","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2026042119564885200_dgaf602-B3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1210\/er.2017-00232","article-title":"The RASopathy family: consequences of germline activation of the RAS\/MAPK pathway","volume":"39","author":"Tajan","year":"2018","journal-title":"Endocr Rev"},{"issue":"12","key":"2026042119564885200_dgaf602-B4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/archdischild-2021-322858","article-title":"Noonan syndrome: improving recognition and diagnosis","volume":"107","author":"Zenker","year":"2022","journal-title":"Arch Dis Child"},{"issue":"6","key":"2026042119564885200_dgaf602-B5","first-page":"1377","article-title":"Deletion mapping of 22q11 in CATCH22 syndrome: identification of a second critical region","volume":"58","author":"Kurahashi","year":"1996","journal-title":"Am J Hum Genet"},{"issue":"10","key":"2026042119564885200_dgaf602-B6","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ng.2734","article-title":"The integrated landscape of driver genomic alterations in glioblastoma","volume":"45","author":"Frattini","year":"2013","journal-title":"Nat Genet"},{"issue":"10","key":"2026042119564885200_dgaf602-B7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/gim.2017.249","article-title":"Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants","volume":"20","author":"Johnston","year":"2018","journal-title":"Genet Med"},{"issue":"6","key":"2026042119564885200_dgaf602-B8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/jmedgenet-2015-103018","article-title":"Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome","volume":"52","author":"Yamamoto","year":"2015","journal-title":"J Med Genet"},{"issue":"1","key":"2026042119564885200_dgaf602-B9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00439-018-1951-7","article-title":"Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes","volume":"138","author":"Umeki","year":"2019","journal-title":"Hum Genet"},{"issue":"1","key":"2026042119564885200_dgaf602-B10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41436-018-0041-5","article-title":"Noonan syndrome associated with growth hormone deficiency with biallelic LZTR1 variants","volume":"21","author":"Nakaguma","year":"2019","journal-title":"Genet Med"},{"issue":"6","key":"2026042119564885200_dgaf602-B11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/cge.13533","article-title":"Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome","volume":"95","author":"Pagnamenta","year":"2019","journal-title":"Clin Genet"},{"issue":"2","key":"2026042119564885200_dgaf602-B12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ajmg.a.61445","article-title":"Providing more evidence on LZTR1 variants in Noonan syndrome patients","volume":"182","author":"Chinton","year":"2020","journal-title":"Am J Med Genet A"},{"issue":"6","key":"2026042119564885200_dgaf602-B13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/hmg\/ddy412","article-title":"Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling","volume":"28","author":"Motta","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"6419","key":"2026042119564885200_dgaf602-B14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1126\/science.aap7607","article-title":"Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination","volume":"362","author":"Steklov","year":"2018","journal-title":"Science"},{"issue":"23","key":"2026042119564885200_dgaf602-B15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1101\/gad.351205","article-title":"NIR is a novel INHAT repressor that modulates the transcriptional activity of p53","volume":"19","author":"Hublitz","year":"2005","journal-title":"Genes Dev"},{"issue":"6","key":"2026042119564885200_dgaf602-B16","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1093\/nar\/gkt1371","article-title":"Transcriptional repressor NIR interacts with the p53-inhibiting ubiquitin ligase MDM2","volume":"42","author":"Heyne","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026042119564885200_dgaf602-B17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12967-023-03877-2","article-title":"Unmasking the biological function and regulatory mechanism of NOC2L: a novel inhibitor of histone acetyltransferase","volume":"21","author":"Lu","year":"2023","journal-title":"J Transl Med"},{"issue":"268","key":"2026042119564885200_dgaf602-B18","doi-asserted-by":"crossref","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","article-title":"Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells","volume":"6","author":"Casado","year":"2013","journal-title":"Sci Signal"},{"issue":"8","key":"2026042119564885200_dgaf602-B19","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","article-title":"Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells","volume":"32","author":"Casado","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2026042119564885200_dgaf602-B20","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/s41467-021-21712-4","article-title":"Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans","volume":"12","author":"Gualtieri","year":"2021","journal-title":"Nat Commun"},{"issue":"W1","key":"2026042119564885200_dgaf602-B21","doi-asserted-by":"crossref","first-page":"W274","DOI":"10.1093\/nar\/gkad297","article-title":"Prediction of protein structures, functions and interactions using the IntFOLD7, MultiFOLD and ModFOLDdock servers","volume":"51","author":"McGuffin","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026042119564885200_dgaf602-B22","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1038\/s41467-024-52587-w","article-title":"QSOX2 Deficiency-induced short stature, gastrointestinal dysmotility and immune dysfunction","volume":"15","author":"Maharaj","year":"2024","journal-title":"Nat Commun"},{"key":"2026042119564885200_dgaf602-B23","doi-asserted-by":"crossref","first-page":"1354699","DOI":"10.3389\/fendo.2024.1354699","article-title":"Gonadal dysfunction in a man with Noonan syndrome from the LZTR1 variant: case report and review of literature","volume":"15","author":"Orsolini","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026042119564885200_dgaf602-B24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000502741","article-title":"LZTR1: genotype expansion in Noonan syndrome","volume":"92","author":"G\u00fcemes","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2026042119564885200_dgaf602-B25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/carcin\/bgw116","article-title":"Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer","volume":"38","author":"Wilczak","year":"2017","journal-title":"Carcinogenesis"},{"issue":"1","key":"2026042119564885200_dgaf602-B26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00401-020-02230-x","article-title":"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis","volume":"141","author":"Mansouri","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2026042119564885200_dgaf602-B27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12920-022-01304-x","article-title":"LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis","volume":"15","author":"Farncombe","year":"2022","journal-title":"BMC Med Genomics"},{"issue":"48","key":"2026042119564885200_dgaf602-B28","doi-asserted-by":"crossref","first-page":"18930","DOI":"10.1073\/pnas.0806556105","article-title":"Role of ERK1\/2 signaling in congenital valve malformations in Noonan syndrome","volume":"105","author":"Krenz","year":"2008","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"2026042119564885200_dgaf602-B29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1089\/ars.2013.5373","article-title":"Autophagy: a crucial moderator of redox balance, inflammation, and apoptosis in lung disease","volume":"20","author":"Nakahira","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"2026042119564885200_dgaf602-B30","doi-asserted-by":"crossref","first-page":"216662","DOI":"10.1016\/j.canlet.2024.216662","article-title":"The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics","volume":"585","author":"Biswas","year":"2024","journal-title":"Cancer Lett"},{"issue":"8","key":"2026042119564885200_dgaf602-B31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ejhg.2011.37","article-title":"Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation","volume":"19","author":"Jongmans","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2026042119564885200_dgaf602-B32","doi-asserted-by":"crossref","first-page":"bvab177","DOI":"10.1210\/jendso\/bvab177","article-title":"GH and senescence: a new understanding of adult GH action","volume":"6","author":"Chesnokova","year":"2022","journal-title":"J Endocr Soc"},{"issue":"9","key":"2026042119564885200_dgaf602-B33","doi-asserted-by":"crossref","first-page":"e12592","DOI":"10.1371\/journal.pone.0012592","article-title":"Long-term IGF-I exposure decreases autophagy and cell viability","volume":"5","author":"Bitto","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"2026042119564885200_dgaf602-B34","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1073\/pnas.1119803109","article-title":"Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature","volume":"109","author":"De Rocca Serra-N\u00e9d\u00e9lec","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026042119564885200_dgaf602-B35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13023-025-03594-7","article-title":"Health outcomes and drug utilisation in children with Noonan syndrome: a European cohort study","volume":"20","author":"Santoro","year":"2025","journal-title":"Orphanet J Rare Dis"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf602\/65052344\/dgaf602.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/1418\/65052344\/dgaf602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/5\/1418\/65052344\/dgaf602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:56:56Z","timestamp":1776815816000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/5\/1418\/8307688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf602","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,1]]}}}